SELLAS Life Sciences Group, Inc. Accounts Payable and Accrued Liabilities
SELLAS Life Sciences Group, Inc. (SLS) had Accounts Payable and Accrued Liabilities of $4.20 million as of 2020-09-30, per its 10-Q filed 2020-11-13.
Discontinued › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent · last filed 2020-11-13
- 2020-09-30: Accounts Payable and Accrued Liabilities $4.20M.
- 2020-06-30: Accounts Payable and Accrued Liabilities $4.30M.
- 2020-03-31: Accounts Payable and Accrued Liabilities $3.60M.
- 2019-12-31: Accounts Payable and Accrued Liabilities $5.30M.
| Period end | Accounts Payable and Accrued Liabilities |
|---|---|
| 2020-09-30 | $4.20M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $4.30M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $3.60M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $5.30M 10-K · filed 2020-03-13 |
| 2019-09-30 | $5.60M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $5.40M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $5.40M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $6.00M 10-K · filed 2019-03-22 |
| 2018-09-30 | $11.90M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $17.10M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $17.20M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $14.90M 10-K · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |